Russell Investments Group Ltd. raised its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 457.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 436,055 shares of the medical research company’s stock after acquiring an additional 357,817 shares during the quarter. Russell Investments Group Ltd.’s holdings in Charles River Laboratories International were worth $128,641,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in the business. Physician Wealth Advisors Inc. boosted its stake in shares of Charles River Laboratories International by 127.9% in the third quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock worth $29,000 after acquiring an additional 55 shares during the period. Continuum Advisory LLC bought a new stake in Charles River Laboratories International during the 2nd quarter valued at approximately $30,000. IFP Advisors Inc lifted its holdings in Charles River Laboratories International by 182.8% in the 3rd quarter. IFP Advisors Inc now owns 164 shares of the medical research company’s stock worth $48,000 after purchasing an additional 106 shares in the last quarter. Compass Wealth Management LLC bought a new position in Charles River Laboratories International in the 3rd quarter worth approximately $69,000. Finally, Activest Wealth Management boosted its stake in Charles River Laboratories International by 25.9% in the 3rd quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock worth $82,000 after purchasing an additional 57 shares during the period. 98.91% of the stock is currently owned by hedge funds and other institutional investors.
Charles River Laboratories International Stock Up 0.1%
Shares of CRL opened at $338.27 on Monday. The stock has a market capitalization of $16.21 billion, a price-to-earnings ratio of 371.73, a price-to-earnings-growth ratio of 3.05 and a beta of 1.36. Charles River Laboratories International, Inc. has a 1 year low of $146.20 and a 1 year high of $379.63. The business’s 50 day simple moving average is $311.21 and its 200-day simple moving average is $228.24. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.41 and a quick ratio of 1.12.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last posted its earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share for the quarter, beating analysts’ consensus estimates of $2.97 by $0.12. Charles River Laboratories International had a net margin of 1.01% and a return on equity of 16.95%. The firm had revenue of $982.73 million during the quarter, compared to analyst estimates of $960.36 million. During the same period last year, the firm posted $2.43 earnings per share. Charles River Laboratories International’s revenue for the quarter was down 2.2% compared to the same quarter last year. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 11.45 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. Morgan Stanley raised their target price on shares of Charles River Laboratories International from $300.00 to $340.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. Piper Sandler set a $300.00 price target on shares of Charles River Laboratories International in a report on Monday, August 10th. Zacks Research cut shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 2nd. Finally, Royal Bank Of Canada increased their price objective on shares of Charles River Laboratories International from $322.00 to $352.00 and gave the company an “outperform” rating in a report on Thursday, November 5th. Thirteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Moderate Buy” and an average target price of $311.67.
Read Our Latest Stock Analysis on CRL
Insider Buying and Selling at Charles River Laboratories International
In other Charles River Laboratories International news, Director James C. Foster sold 33,561 shares of the stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $300.00, for a total transaction of $10,068,300.00. Following the completion of the transaction, the director owned 31,596 shares in the company, valued at $9,478,800. This trade represents a 51.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon Parisotto sold 2,156 shares of Charles River Laboratories International stock in a transaction dated Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total value of $742,547.96. Following the completion of the transaction, the executive vice president owned 4,807 shares of the company’s stock, valued at approximately $1,655,578.87. This represents a 30.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 63,352 shares of company stock worth $20,291,281 over the last 90 days. 1.30% of the stock is owned by insiders.
Charles River Laboratories International Profile
Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.
Read More
- Five stocks we like better than Charles River Laboratories International
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Free Report).
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
